SNORA74D: A Small Nucleolar RNA with Promising Potential as a Drug Target

Target Name: SNORA74D

NCBI ID: G109616975

SNORA74D

Other Name(s): small nucleolar RNA, H/ACA box 74D | Small nucleolar RNA, H/ACA box 74D

SNORA74D: A Small Nucleolar RNA with Promising Potential as a Drug Target

Introduction

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a critical role in various cellular processes, including chromatin regulation, gene expression, and translation. H/ACA box 74D (SNORA74D) is a specific snRNA that has been identified as a potential drug target and biomarker. In this article, we will explore the biology of SNORA74D and its potential as a drug target.

Biology of SNORA74D

SNORA74D is a 24.5 kilobase (kb) long RNA molecule that is found in the nucleolus of eukaryotic cells. It is part of the H/ACA box family of snRNAs, which are known for their ability to interact with DNA-binding proteins and play a role in chromatin regulation. SNORA74D is characterized by the presence of a highly conserved alpha-helices region, a unique feature of this class of snRNAs.

SNORA74D has been shown to play a role in regulating gene expression and has been associated with various cellular processes, including cell growth, apoptosis, and translation. For example, studies have shown that SNORA74D is involved in the regulation of the expression of the tumor suppressor gene, TP53. TP53 is a well-known gene that is often mutated in cancer and is involved in the maintenance of genomic stability. SNORA74D has been shown to play a role in regulating the expression of TP53 by binding to its promoter region and preventing its degradation.

In addition to its role in gene expression, SNORA74D has also been shown to be involved in the regulation of translation. Studies have shown that SNORA74D is a binding partner of the protein translation factor, TFII4, and that it plays a role in regulating the translation of SNORA74D-containing RNAs. This suggests that SNORA74D may be a potential drug target for translation-related diseases.

Potential Therapeutic Applications

SNORA74D has the potential to be a drug target due to its unique biology and the involvement it is involved in. There are several potential therapeutic applications for SNORA74D, including:

1. Cancer treatment: SNORA74D has been shown to play a role in the regulation of the expression of the tumor suppressor gene, TP53. Therefore, targeting SNORA74D may be a promising strategy for cancer treatment.
2. Neurodegenerative diseases: Studies have shown that SNORA74D is involved in the regulation of translation and that it may be involved in the development of neurodegenerative diseases. Therefore, targeting SNORA74D may be a promising strategy for the development of new treatments for neurodegenerative diseases.
3. Infectious diseases: SNORA74D has been shown to play a role in the regulation of gene expression and has been associated with various cellular processes. Therefore, targeting SNORA74D may be a promising strategy for the development of new treatments for infectious diseases.

Conclusion

SNORA74D is a small nucleolar RNA that has been shown to play a critical role in various cellular processes and has the potential to be a drug target. Its unique biology and involvement in the regulation of gene expression, translation, and cellular processes make it an attractive target for research and development of new therapies. Further studies are needed to fully understand the biology of SNORA74D and its potential as a drug

Protein Name: Small Nucleolar RNA, H/ACA Box 74D

The "SNORA74D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA74D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets